Triangle, Mitusubishi Chemical Corp. deal

Triangle will develop the Japanese company's non-nucleoside reverse transcriptase inhibitor, MKC-442, to treat HIV. Mitsubishi will pay for development at Triangle from preclinical through Phase I and...